The objective of this study was to confirm if two formulations of isotretionin (capsules) are bioequivalent. Test product was Oratane® 20 mg (Laboratorios Dermatológicos Darier) and reference product Roaccutan® 20 mg (Productos Roche). Two capsules administered together were the single dosage. The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fed conditions. The population was composed of 36 healthy volunteers, male adults between 18-45 years. The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
36
Roaccutan 2 capsules of 20 mg; reference drug
Oratane 2 capsules of 20 mg; test drug
GSK Investigational Site
Monterrey, Nuevo León, Mexico
Peak Plasma Concentration (CMAX) of isotretinoin
pharmacokinetics
Time frame: 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours postdosage
Area under the plasma concentration versus time curve (AUC) of isotretionin
pharmacokinetics
Time frame: 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours postdosage
Incidence od adverse events
Safety
Time frame: 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.